Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galapagos NV
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
England’s health technology appraisal body NICE has recommended Galapagos’ Jyseleca for ulcerative colitis, Takeda’s Revestive for short bowel syndrome and Zogenix’s Fintepla for seizures associated with Dravet syndrome.
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
- Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
- Abound Bio, Inc.
- CellPoint B.V.
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.